{
  "content": "1160 Cost-Effectiveness of Drugs for Atrial Fibrillation  similar in all groups, and efficacy was assumed to be relatively constant. To ensure patient follow-up for a lifetime, a cycle length of year and a time horizon of 20 years were used. Each year, the cohort accrued costs and quality-adjusted life years (QALY) depending on which health state they inhabited. The model was built in TreeAge Pro 2012 (TreeAge Software, Inc., Williamstown, MA, USA).",
  "source": "https://pdfs.semanticscholar.org/798d/e6aa4ebeb8836fdffb27a98ab4195330069c.pdf",
  "chunk_id": "00253a40-3bf7-4ba1-81fa-062c8852b7b5",
  "similarity_score": 0.2743831276893616,
  "query": "cost effectiveness economic analysis amiodarone beta-blockers atrial fibrillation healthcare costs hospitalization reduction",
  "rank": 21,
  "title": "Cost-effectiveness of rate- and rhythm-control drugs for treating atrial fibrillation in Korea",
  "authors": "Min Kim, Woojin Kim, Changsoo Kim, Boyoung Joung",
  "year": "2019",
  "journal": "Yonsei Medical Journal",
  "reference": "Kim, M., Kim, W., Kim, C., & Joung, B. (2019). Cost-effectiveness of rate- and rhythm-control drugs for treating atrial fibrillation in Korea. Yonsei Medical Journal, 60(12), 1157-1163. https://doi.org/10.3349/ymj.2019.60.12.1157",
  "doi": "10.3349/ymj.2019.60.12.1157",
  "chunk_index": 25,
  "total_chunks": 62,
  "retrieved_at": "2025-07-24T21:58:16.915804"
}